|
Modiquest Research B.V. Mobile +31 (0)6 16940490 info@modiquestresearch.com
|
![]() |
|
|
Visiting address: Innovation lab |
Postal address: Schoutstraat 58 |
Delivery address: ModiQuest Research |
|
ModiQuest Research, founded early 2005 as a private company, is a Contract Research Organisation focused on the generation of recombinant monoclonal antibodies from various species. ModiQuest Research focuses on feasibility, early development, and pilot scale research projects in the recombinant antibody field. More in particular, ModiQuest Research is specialized in the generation of antibodies against difficult targets, such as antibodies specific for post-translationally modified (neo) epitopes. |
| |
ModiQuest Research uses various state of the art technologies for the generation of (recombinant) monoclonal antibodies from various origin (experience with mouse, chicken, llama and human; other species on request). To distinguish itself from potential competitors and to be able to offer proprietary services, Modiquest Research has obtained technology licenses from third parties. Next to that, ModiQuest Research offers to work under proprietary technology patents (e.g. broad phage display experience available using various antibody formats) for clients. |
|
ModiQuest Research also sells novel antibodies for research and diagnostic applications and for the generation of animal models, like collagen antibody induced arthritis (CAIA). For the latter animal model under collaboration with third parties also animal studies are offered by ModiQuest Research.
|
![]() |
ModiQuest Research is a contract research organisation focused on generation of recombinant monoclonal antibodies from various species (animal, human). ModiQuest Research uses state of the art technologies like antigen specific B-cell selection, combined with efficient hybridoma generation, or direct antibody cDNA cloning from selected B-cells. ModiQuest Research also offers custom phage display services.
Contract research is performed in close collaboartion with Modiquest B.V.
ModiQuest Research offers Contract Research Expertise and Facilities for Technology Development in the Recombinant Antibody Field:
|
![]() |
ModiQuest Research focuses on feasibility, early development and pilot scale research projects in the recombinant antibody field. We specialize in the generation of antibodies against difficult targets such as antibodies specific for post-translationally modified (neo) epitopes.
ModiQuest Research offers state of the art technology access to:
|
|
For downloading brochures, please click here.
ModiQuest Research uses
| Antigen specific B-cell selection offers a fast and efficient opportunity to obtain (recombinant) antibodies from various species (i.e. mouse, human, llama, chicken, rabbit etc.).
Difficult and rare antibody specificities can be generated using B-cell panning technology. |
|
| ModiQuest Research focuses on the generation of antibodies specific for post-translationally modified (neo) epitopes. For more information please click here (PDF 2Mb). |
|
Next to that under collaboration with third parties animal studies using these CAIA antibodies are offered by ModiQuest Research. For inquiries about full animal studies using the MQR-CAIA model please contact ModiQuest Research directly.
Please click here for downloading a spec. sheet about the MQR-CAIA antibody model. |
|
Collagen-induced arthritis is an antibody mediated disease. Therefore, type II collagen specific antibodies can be used to induce arthritis in mice. Our mixture of type II collagen specific antibodies (2.6mg per animal) induces severe inflammation in the ankle and paws of DBA mice which resemble many aspects of arthritis. One of the biggest advantages of our monoclonal antibody-induced arthritis model is that severe arthritis is induced within 24-48 hours instead of the four weeks required to induce arthritis after immunization with type II collagen. ModiQuest Research recommends highly susceptible DBA/1 mice. Other strains may be used, however the amount of antibody cocktail required may vary. Thus, this model is ideal for rapidly screening therapeutics for the treatment of arthritis and to study the mechanisms involved in the development of arthritis. |
|
ModiQuest Research has available an unique Hi-tech facility to generate high producing primary cells and stable cell lines.
MQR has a large set of expression vectors available allowing the generation of stable recombinant antibody expressing cell lines using, by the customer provided, hybridomas, cDNA or sequences. Various Mouse and Human isotypes as well as Chicken based recombinant (chimeric) antibody producing cell lines can be generated very efficiently.
ModiQuest Research offers
ModiQuest Research (MQR) focusses on the generation of stable, high level, antibody producing cell lines (using AMAXA Nucleofection, high throughput ClonePix technology, and optimised MQR vector systems).
|
Technology (PPS 8Mb) |
For more information please click here (PDF 2Mb). |
ModiQuest Research
|
![]() |
| For an overview of our antibodies and to purchase our antibodies online, please click here to go to our webshop. |
| ModiQuest Research has developed a sensitive Antibody Based Assay to test for Peptidyl Arginine Deiminase (PAD) activity (ABAP). The ABAP is an Enzyme Linked-Immuno-Sorbent Assay (ELISA) for the determination of PAD enzyme activity in cell and tissue lysates.
Please click here to go to our online shop directly.
|
|
PAD enzymes are transcriptional co-regulators that catalyze the calcium dependent conversion of specific arginine residues present in for instance histones to citrulline. In diseases such as multiple sclerosis and rheumatoid arthritis (RA) these PAD enzymes seem to be dysregulated. For instance in RA these enzymes become active when they exit the cell in regions of joint inflammation where they deiminate arginines in proteins such as vimentin and fibrinogen. The level of PAD activity has been correlated with RA severity. The ABAP test is also suitable for determining PAD activity of purified recombinant PAD enzymes used in various bioassays.
|
![]() |
|
The MQR-ABAP test is a powerful method to rapidly screen for PAD activity. Compared to currently used assays for PAD activity determination such as the DAMO BAEE conversion test the MQR-ABAP assay is more robust, and at least 500 times more sensitive. The ABAP kit consists of: 1) 96-well plate coated with Arginine containing peptides 2) A ModiQuest Research mouse PAD enzyme for activity calibration 3) a proprietary ModiQuest Research HRP-labelled monoclonal antibody specifically binding deiminated arginines. A detalied spec. sheet for the ABAP test can be downloaded by clicking here (PDF 192Kb). |
Recombinant human and mouse Peptidyl Argininge Deiminase (PAD) enzymes.
|
ModiQuest Research provides purified recombinant human and mouse Peptidyl Arginine Deiminase (PAD) enzymes for research applications.
|
![]() |
|
PAD enzymes can be used for the deimination of cell lysates and proteins which will facilitate the proteomic analysis and identification of compounds that may be involved in the ontogeny of various autoimmune diseases like Rheumatoid Arthritis and Multiple Sclerosis.
For more information please click here (PDF 1.54Mb). |

Bio2008, San Diego
ModiQuest Research will be attending the 2008 BIO International Convention in San Diego coming June. Please, come visit us at booth 3135 at the Holland Pavilion or meet us using the partnering system!
|
|
ModiQuest and ProteoNic announce collaboration Press Release - June 9, 2008 Today ModiQuest and ProteoNic announce their collaboration on antibody expression in mammalian cell culture for use in diagnostic and therapeutic product development and manufacturing. ProteoNic will provide its expertise in construct design and protein expression optimization. ModiQuest will apply its proprietary vectors systems and expertise in high throughput production of high level expressing mammalian cell lines in combination with the UNic™ expression technology to manufacture its commercial antibodies in mammalian cell lines.
Both companies will be attending the upcoming BIO International Convention, to be held June 17-20 in Jos Raats, Managing Director ModiQuest commented: “ModiQuest is most pleased with this current collaboration. Implementation of ProteoNic’s expression optimization cassettes will enable us to develop even better expression vectors and will allow faster progress of our therapeutic and diagnostic programs based on biologicals. Moreover, implementation of ProteoNic’s UNic™ expression enhancement technology in our expression systems will enable us to offer fast production of even higher protein expressing cell lines for our own programs and as third party services to our customers.”
“This collaboration is another great opportunity to expand the validation and track record of the application of our UNic™ expression technology in mammalian cell culture”, ProteoNic CEO Victor Schut commented. “ModiQuest’s expertise in antibody expression strongly supports our technology development and experience in optimizing translation efficiency for a relevant group of commercial proteins commonly expressed in mammalian cell lines. Consequently, our collaboration will provide significant added value beneficial to the clients of ModiQuest. We are very pleased to have created a strong and mutually beneficial long term partnership supporting both scientific and commercial goals.”
--------------------- ModiQuest is a young and dynamic biotech company, with a focus on high throughput generation of (recombinant) fully human and animal derived antibodies, especially for use as therapeutics and diagnostics in autoimmune diseases, infectious diseases and cancer. ModiQuest generates antibodies from both human and animal origin using a large panel of state-of-the-art technologies, such as B-cell selection and phage display applications. For more information visit www.modiquestresearch.com
About ProteoNic
ProteoNic specializes in optimizing messenger RNA (translation machinery) applying its UNic™ expression technology to significantly boost upstream protein production in a wide range of biological host systems. ProteoNic aims at establishing the UNic™ technology as the state-of-the-art standard within the protein-based industries. This technology will result in significantly higher yields, improvements in quality and manufacturing flexibility in the context of lower production costs. To demonstrate this, ProteoNic has partnered with a number of companies active in various biotech applications. www.proteonic.nl |
|
|
Discover Your Potential
|
By working under the clients’ proprietary patents, proprietary technologies and ModiQuest Research`s experience, including library construction (sdab, scfv, fab) and library screening, are combined. |
|
|
Mouse monoclonals |
|||
| Please click here to go to our online shop directly | |||
| Please click on catalogue no. for spec sheets | |||
| Human RNase MRP complex | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-1.201 | hRpp20 | 1F11 | IgG2a |
| Human Exosome complex | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-2.103 | hRrp4 | 15B3 | IgG1 |
| Human collagen I | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-3.101 | hcol I | 2G8 | IgM |
| # MQ-3.102 | hcol I | 9D7 | IgG1 |
| Bovine collagen II | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-4.116 | m/b Col II | 12F6 | IgG1 |
| Collagenase | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-5.101 | collagenase | 1D2 | IgG2b |
| Enhanced Blue Fluorescent Protein | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-6.102 | EBFP | 3A6 | IgG1 |
| # MQ-6.103 | EBFP | 6G9 | IgG1 |
| # MQ-6.104 | EBFP | 7F10 | IgG1 |
| Glutathionine S-transferase | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-7.102 | GST | 2A9 | IgG2a |
| Histidine Tag | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-8.101 | His 6x | 5B12 | IgG2b |
| Mouse protein tyrosine phosphatase PTP-BL PDZ domain 2 | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-9.102 | mPDZ2 | 4B6 | IgG1 |
| Mouse protein tyrosine phosphatase gene Ptprr | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-10.101 | PTPBR7, PTP-SL, PTPPBSg, STEP | 6A6 | IgG |
Modiquest Research offers
Furthermore we offer
|
|
Learn more about our ClonePix technology
|
Technology (PPS 2Mb) |
| Human monoclonals | |||
| Please click here to go to our online shop directly | |||
| Please click on catalogue no. for spec sheets | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQ-12.103 | unknown | IgG2/kappa | |
| Anti citrulline cotaining peptide antibodies | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQR2.101 | Citrullinated Fibrinogen | ||
| # MQR2.102 | Citrullinated Fibrinogen | ||
| # MQR2.104 | Citrullinated Fibrinogen | ||
| Anti human auto-antigen antibodies | |||
| Catalogue no. | Antigen | Clone no. | Isotype |
| # MQR 2.301 | hU1-C protein | ||
| # MQR 2.401 | hJo-1 protein | ||
| # MQR 2.201 | hU1-70K protein, 40 kD apoptotic cleavage product | ||

Bio2007, Boston, May 5 -
ModiQuest Research will be attending the 2007 BIO International Convention in Boston starting coming May 7th. Please, come visit us at booth 2633 at the Holland Pavilion or meet us using the partnering system!
Download ModiQuest Research brochures.
![]() |
||
|
Corporate overview (2MB) |
Collagen Antibody Induced Arthritis Mouse Model (2MB)
|
|
|
Stable recombinant antibody producing cell line generation (2MB) |
Download ModiQuest Research company brochures.
Click on the language you require:
Dutch |
Chinese |
German |
Japanese |
English |
French |
Spanish |
Italian |
|
ModiQuest and Pepscan to collaborate on the identification of "me-too" monoclonal antibodies and monoclonal antibodies against intractable targets
Press Release - June 12, 2008
Nijmegen and Lelystad, The . ModiQuest Research and Pepscan announced today the start of a research collaboration to identify human and animal derived "me-too" monoclonal antibodies and monoclonal antibodies against intractable disease targets. These targets include membrane proteins like GPCRs and ion channels.
Using its proprietary CLIPS™ technology Pepscan will generate functional mimics of intractable targets. ModiQuest will apply various methods like proprietary B-cell selection and cloning, or phage display to generate potent functional antibodies against mimics of the essential parts of such intractable targets.
Both companies will be attending the upcoming BIO International Convention, to be held June 17- Jos Raats , Managing Director of ModiQuest commented: “ModiQuest is very pleased with this collaboration. Combining the exceptional strength of Pepscan’s CLIPSTM technology and ModiQuest’s unique combination of antibody-generating technologies (fully human or animal derived), will allow for the generation of novel therapeutic and diagnostic antibodies, for application in the fields of autoimmune diseases, infectious diseases, and cancer”.
Rob Meloen, CSO of Pepscan Therapeutics comments: “I am excited about this collaboration with ModiQuest as it will give Pepscan access to monoclonal antibody technologies and capabilities, thus expanding our product scope beyond therapeutic vaccines into monoclonal antibodies”.
--------------------- ModiQuest Research is a young and dynamic biotech company, with a focus on high throughput generation of (recombinant) fully human and animal derived antibodies, especially for use as therapeutics and diagnostics in autoimmune diseases, infectious diseases and cancer. ModiQuest Research generates antibodies from both human and animal origin using a large panel of state-of-the-art technologies, such as B-cell selection and phage display applications. For more information please visit: www.modiquestresearch.com
About Pepscan
Pepscan Therapeutics is a product focused immunotherapy company based in the
|
|
|
|
Discover Your Potential |
|
|

ModiQuest Research participated in a Multi-Sectoral Economic Mission to Taiwan 14-19 September 2008.
This successful mission was organised by the Joint Business Council Nederland – Taiwan, a division of the Netherlands Council for Trade Promotion.

Biotechnica 2008, Hannover
ModiQuest Research will be attending the 2008 Biotechnica in Hannover, Germany, 7-9 October 2008.
Please, come visit us at Stand G12, in Hall 9!
For pdf download of our company profile click here.
For pdf download of our company for partnering options please click here.
Scottish Bio Industry and the Dutch BioFarmind